Don't Take a Position in Roivant Sciences Stocks Without Knowing Its Fundamentals!

By Susan Ramirez • Tuesday, September 12 10:43 • Permanent Link

Mid-cap Health Care company Roivant Sciences has moved -1.3% so far today on a volume of 650,478, compared to its average of 5,126,682. In contrast, the S&P 500 index moved -0.0%.

Roivant Sciences trades -27.29% away from its average analyst target price of $15.63 per share. The 8 analysts following the stock have set target prices ranging from $12.0 to $23.0, and on average have given Roivant Sciences a rating of buy.

Anyone interested in buying ROIV should be aware of the facts below:

Roivant Sciences has moved 201.0% over the last year, and the S&P 500 logged a change of 15.0%
Based on its trailing earnings per share of -1.46, Roivant Sciences has a trailing 12 month Price to Earnings (P/E) ratio of -7.8 while the S&P 500 average is 15.97
ROIV has a forward P/E ratio of -9.6 based on its forward 12 month price to earnings (EPS) of $-1.18 per share
Its Price to Book (P/B) ratio is 9.57 compared to its sector average of 4.16
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas.
Based in London, the company has 904 full time employees and a market cap of $8.86 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.